ArticleWorld journal of surgical oncology2026
Impact of neoadjuvant imatinib duration and tumor response on recurrence-free survival in locally advanced gastrointestinal stromal tumors: a retrospective multicenter cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundNeoadjuvant imatinib (IM) is widely used in locally advanced gastrointestinal stromal tumors (GISTs) to improve resectability and reduce recurrence, but optimal duration and the prognostic role of tumor response remain unclear.
methodsWe performed a multicenter retrospective cohort study of patients with locally advanced GISTs who received preoperative imatinib and surgery between 2014 and 2024 at four tertiary centers in China. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and a novel parameter, the Percent Tumor Response Index (PTRI), was proposed to integrate baseline size with shrinkage rate. Recurrence-free survival (RFS) and overall survival (OS) were analyzed by Kaplan–Meier and Cox regression.
resultsAmong 168 patients (median treatment 7.5 months), all achieved disease control: partial response (PR) in 52.4% and stable disease (SD) in 47.6%. Median tumor size decreased from 10.0 to 7.0 cm (p < 0.001). After a median follow-up of 53 months, 3- and 5-year RFS rates were 88.6% and 83.2%, and OS rates were 97.6% and 92.0%. Using maximally selected rank statistics (MSRS), 8 months was identified as a potentially meaningful threshold. Patients treated ≤ 8 months had superior RFS compared with > 8 months. In multivariable Cox regression analysis, a preoperative imatinib duration exceeding 8 months (HR 2.40, p = 0.034) and a postoperative mitotic count > 5/5 HPF (HR 2.31, p = 0.042) were independently associated with worse RFS, whereas a higher Percent Tumor Response Index (PTRI), a newly proposed exploratory metric, was associated with a reduced risk of recurrence, corresponding to a 32% risk reduction per unit increase (p = 0.002).
conclusionsIn our cohort, a preoperative imatinib duration exceeding 8 months for locally advanced GISTs was associated with inferior RFS. Elevated PTRI predicted favorable recurrence outcomes, whereas higher postoperative mitotic count indicated poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.